Why doctors don't think vaccine skeptics' acceptance of a helpful COVID-19 treatment is sufficient

Monoclonal antibodies produced by Regeneron and Eli Lilly have become widely accepted as a successful treatment for COVID-19, reducing symptoms quickly and keeping infected people out of the hospital if they act quickly enough. Doctors and vaccine skeptics alike are proponents, but some medical experts argue the antibodies aren't enough on their own to make up for the slow-down in vaccine uptake, The New York Times reports.
The simple explanation is that the more people who get vaccinated, the fewer people there will be who need any sort of coronavirus remedy. Beyond that, the infusions also take a lot of time and require a lot of attention from hospital staff. They're also more expensive, costing the federal government about $2,100 per dose. "It's clogging up resources, it's hard to give, and a vaccine is $20 and could prevent almost all of that," Dr. Christian Ramers, an infectious disease specialist and the chief of population health at Family Health Centers of San Diego, told the Times. Basically, Ramers said, emphasizing monoclonal antibodies and playing down vaccines is akin to "investing in car insurance without investing in brakes."
The other worry is that they can't keep up with the pace of more serious outbreaks. For starters, the treatments only help individual patients, whereas vaccines have a snowball effect, and they also don't provide protective immunity (though the patients would have acquired natural immunity through their infection), the Times notes. Ultimately, while monoclonal antibodies are a vital tool in fighting the coronavirus, "something like that just doesn't scale," Dr. Howard Huang, the medical leader for Houston Methodist's infusion program, told the Times. Read more at The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Today's political cartoons - March 8, 2025
Cartoons Saturday's cartoons - trade wars, healthcare costs, and more
By The Week US Published
-
Marbled tea eggs recipe
The Week Recommends With a beautiful exterior, these eggs are also marked by their soft yolk
By The Week UK Published
-
The Washington Post: kowtowing to Trump?
Talking Point The newspaper's opinion editor has handed in his notice following edict from Jeff Bezos
By The Week UK Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published